In the growing field of personalized medicine, scientists at Yale University have found promising evidence that a simple ...
Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...
Onvida Health is bringing a new era of precision and early detection to lung cancer care in Yuma. The hospital has introduced ...
Charles took part in 372 public engagements last year, even after stepping aside for almost three months because of cancer ...
Dr. Ajaz Khan is the chief of medical oncology at City of Hope Chicago. He oversees the Illinois hospital’s staff of cancer ...
BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...
The Hearty Soul on MSN1d
High-Sugar Diet Linked to Lung Cancer, Expanding Our Understanding of Diet's ImpactWe all know at this point that high-sugar diets are not good for us. They increase our risk of developing cardiovascular ...
RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored ...
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.
Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback